References from scientific journals

Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.

Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Gevaert P, et al. J Allergy Clin Immunol. 2020 Sep;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032. Epub 2020 Jun 7. J Allergy Clin Immunol. 2020. PMID: 32524991 Free article. Clinical Trial.

METHODS: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and intranasal mometasone for 24 weeks. Coprimary end points included change from baseline to week 24 in Nasal Polyp Score (NPS) and Nasal Cong …
METHODS: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and intran …

Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids.

Spada F, Barnes TM, Greive KA. Spada F, et al. Australas J Dermatol. 2018 Aug;59(3):e168-e174. doi: 10.1111/ajd.12762. Epub 2018 Feb 7. Australas J Dermatol. 2018. PMID: 29411351 Free PMC article. Review.

Derivatives of hydrocortisone, such as mometasone furoate, a (2') furoate-17 ester with chlorine substitutions at positions 9 and 21, have been designed to improve efficacy and reduce the incidence of adverse effects. ...Sensitisation to mometasone …
Derivatives of hydrocortisone, such as mometasone furoate, a (2') furoate-17 ester with chlorine substitutions at posit …

Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial.

Abdelalim AA, Mohamady AA, Elsayed RA, Elawady MA, Ghallab AF. Abdelalim AA, et al. Am J Otolaryngol. 2021 Mar-Apr;42(2):102884. doi: 10.1016/j.amjoto.2020.102884. Epub 2021 Jan 4. Am J Otolaryngol. 2021. PMID: 33429174 Free PMC article. Clinical Trial.

OBJECTIVES: To evaluate the role of the topical corticosteroid, mometasone furoate, nasal spray in the treatment of post COVID-19 anosmia. ...One hundred patients were randomly assigned to two groups; group I included 50 patients received mometasone furoat …
OBJECTIVES: To evaluate the role of the topical corticosteroid, mometasone furoate, nasal spray in the treatment of post COVID …

Different types of intranasal steroids for chronic rhinosinusitis.

Chong LY, Head K, Hopkins C, Philpott C, Burton MJ, Schilder AG. Chong LY, et al. Cochrane Database Syst Rev. 2016 Apr 26;4:CD011993. doi: 10.1002/14651858.CD011993.pub2. Cochrane Database Syst Rev. 2016. PMID: 27115215 Free article. Review.

The evidence was of very low quality. Fluticasone propionate versus mometasone furoate We identified only one study (100 participants with polyps) that evaluated disease severity (nasal symptoms scores), which reported no difference (no numerical data available). .. …
The evidence was of very low quality. Fluticasone propionate versus mometasone furoate We identified only one study (100 parti …

Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.

van Zyl-Smit RN, Krüll M, Gessner C, Gon Y, Noga O, Richard A, de Los Reyes A, Shu X, Pethe A, Tanase AM, D'Andrea P; PALLADIUM trial investigators. van Zyl-Smit RN, et al. Lancet Respir Med. 2020 Oct;8(10):987-999. doi: 10.1016/S2213-2600(20)30178-8. Epub 2020 Jul 9. Lancet Respir Med. 2020. PMID: 32653075 Clinical Trial.

The objective of the PALLADIUM study was to assess the efficacy and safety of once-daily FDC of mometasone furoate plus indacaterol acetate (MF-IND) versus mometasone furoate (MF) monotherapy in patients with inadequately controlled asthma. ...
The objective of the PALLADIUM study was to assess the efficacy and safety of once-daily FDC of mometasone furoate plus indaca …

Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review.

Gupta AK, Versteeg SG. Gupta AK, et al. Am J Clin Dermatol. 2017 Apr;18(2):193-213. doi: 10.1007/s40257-016-0232-2. Am J Clin Dermatol. 2017. PMID: 27804089 Review.

Pimecrolimus, the focus of seven of the 32 eligible studies, was the most commonly studied topical treatment. CONCLUSION: Promiseb(), desonide, mometasone furoate, and pimecrolimus were found to be effective topical treatments for facial SD, as they had the lowest r …
Pimecrolimus, the focus of seven of the 32 eligible studies, was the most commonly studied topical treatment. CONCLUSION: Promiseb(), desoni …

Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.

Bachert C, Hellings PW, Mullol J, Hamilos DL, Gevaert P, Naclerio RM, Joish VN, Chao J, Mannent LP, Amin N, Abbe A, Taniou C, Fan C, Pirozzi G, Graham NMH, Mahajan P, Staudinger H, Khan A. Bachert C, et al. Allergy. 2020 Jan;75(1):148-157. doi: 10.1111/all.13984. Epub 2019 Oct 23. Allergy. 2020. PMID: 31306495 Clinical Trial.

In a previously reported randomized clinical trial (NCT01920893), addition of dupilumab to mometasone furoate in patients with CRSwNP refractory to intranasal corticosteroids (INCS) significantly improved endoscopic, radiographic, and clinical endpoints and patient- …
In a previously reported randomized clinical trial (NCT01920893), addition of dupilumab to mometasone furoate in patients with …

As-needed ICS-LABA in Mild Asthma: What Does the Evidence Say?

Domingo C, Rello J, Sogo A. Domingo C, et al. Drugs. 2019 Nov;79(16):1729-1737. doi: 10.1007/s40265-019-01202-0. Drugs. 2019. PMID: 31584145 Review.

Finally, the SIENA study showed that 73% of patients with mild asthma do not have an eosinophilic phenotype and that these patients have a similar clinical response to ICS (mometasone) and antimuscarinic drugs (tiotropium), results that challenge the indication of a drug c …
Finally, the SIENA study showed that 73% of patients with mild asthma do not have an eosinophilic phenotype and that these patients have a s …

Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).

Gessner C, Kornmann O, Maspero J, van Zyl-Smit R, Krüll M, Salina A, Gupta P, Bostel S, Fucile S, Conde LG, Pfister P. Gessner C, et al. Respir Med. 2020 Aug-Sep;170:106021. doi: 10.1016/j.rmed.2020.106021. Epub 2020 May 27. Respir Med. 2020. PMID: 32843164 Clinical Trial.

BACKGROUND: The efficacy and safety of once-daily (o.d.) fixed-dose combination of indacaterol (IND), glycopyrronium (GLY) and mometasone furoate (MF) via Breezhaler versus concurrent administration of salmeterol/fluticasone (SAL/FLU) twice-daily (b.i.d.) via Accuha …
BACKGROUND: The efficacy and safety of once-daily (o.d.) fixed-dose combination of indacaterol (IND), glycopyrronium (GLY) and mometasone …

A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps.

Kern RC, Stolovitzky JP, Silvers SL, Singh A, Lee JT, Yen DM, Iloreta AMC Jr, Langford FPJ, Karanfilov B, Matheny KE, Stambaugh JW, Gawlicka AK; RESOLVE II study investigators. Kern RC, et al. Int Forum Allergy Rhinol. 2018 Apr;8(4):471-481. doi: 10.1002/alr.22084. Epub 2018 Jan 19. Int Forum Allergy Rhinol. 2018. PMID: 29350840 Free PMC article. Clinical Trial.

A corticosteroid-eluting sinus implant was designed to address these limitations in patients with recurrent polyposis after sinus surgery by delivering 1350 mug of mometasone furoate (MF) directly to the ethmoid sinus mucosa over approximately 90 days. ...
A corticosteroid-eluting sinus implant was designed to address these limitations in patients with recurrent polyposis after sinus surgery by …